ArticleInvestigational new drugs2023

A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.

Zhuang Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.